Pfizer Inc.
Pfizer Provides Full-Year 2025 Guidance and Reaffirms 2024 Guidance
Summary
Pfizer Inc. has provided its full-year 2025 financial guidance, anticipating revenues between $61.0 to $64.0 billion and Adjusted diluted EPS between $2.80 to $3.00. The company also reaffirmed its full-year 2024 financial guidance. Pfizer expects operational growth of approximately flat to 5% in revenues and operational earnings growth of 10% to 18% for 2025, excluding certain non-recurring items. The guidance includes an expected unfavorable impact from the Inflation Reduction Act changes in 2025. A press release with detailed guidance is furnished as Exhibit 99.1.
Get alerts for PFE
Be first to know when Pfizer Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Pfizer Inc.
Pfizer Inc. is a multinational pharmaceutical and biotechnology corporation, recognized for its role in the research, development, and manufacturing of healthcare products. Operating in the health sector, Pfizer focuses on creating innovative medicines and vaccines that significantly improve patients' lives. It is renowned for its contributions to pivotal health areas, such as oncology, immunology, cardiovascular health, and rare diseases. Pfizer maintains a robust pipeline of products at various stages of clinical development, enhancing its market position and impact. The company is instrumental in the global pharmaceutical landscape, contributing to public health with breakthroughs like vaccines and therapies that tackle some of the world's most challenging diseases. Headquartered in New York City, Pfizer plays a critical role in addressing urgent medical needs worldwide and is involved in extensive collaborations with scientific communities and healthcare systems. As a key player in the pharmaceutical industry, Pfizer’s developments and strategic initiatives can influence market trends and health policies, underscoring its importance in the global effort to combat health issues.
Official SEC Documents
Advertisement